BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Simon AK, Williams O, Mongkolsapaya J, Jin B, Xu XN, Walczak H, Screaton GR. Tumor necrosis factor-related apoptosis-inducing ligand in T cell development: sensitivity of human thymocytes. Proc Natl Acad Sci USA. 2001;98:5158-5163. [PMID: 11309507 DOI: 10.1073/pnas.091100398] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Gamie Z, Kapriniotis K, Papanikolaou D, Haagensen E, Da Conceicao Ribeiro R, Dalgarno K, Krippner-Heidenreich A, Gerrand C, Tsiridis E, Rankin KS. TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: Pre-clinical and clinical data. Cancer Lett 2017;409:66-80. [PMID: 28888998 DOI: 10.1016/j.canlet.2017.08.036] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
2 Crowder RN, Zhao H, Chatham WW, Zhou T, Carter RH. B lymphocytes are resistant to death receptor 5-induced apoptosis. Clin Immunol 2011;139:21-31. [PMID: 21276756 DOI: 10.1016/j.clim.2010.12.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
3 Chen MC, Kuo YC, Hsu CM, Chen YL, Shen CC, Teng CM, Pan SL. The apoptotic mechanisms of MT-6, a mitotic arrest inducer, in human ovarian cancer cells. Sci Rep 2017;7:46149. [PMID: 28387244 DOI: 10.1038/srep46149] [Reference Citation Analysis]
4 Koliaki C, Katsilambros N. Repositioning the Role of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) on the TRAIL to the Development of Diabetes Mellitus: An Update of Experimental and Clinical Evidence. Int J Mol Sci 2022;23:3225. [PMID: 35328646 DOI: 10.3390/ijms23063225] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Roberts AI, Devadas S, Zhang X, Zhang L, Keegan A, Greeneltch K, Solomon J, Wei L, Das J, Shi Y, Sun E, Liu C, Yuan Z, Zhou J. The Role of Activation-Induced Cell Death in the Differentiation of T-Helper-Cell Subsets. IR 2003;28:285-94. [DOI: 10.1385/ir:28:3:285] [Cited by in Crossref: 48] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
6 Daniels RA, Turley H, Kimberley FC, Liu XS, Mongkolsapaya J, Ch'En P, Xu XN, Jin BQ, Pezzella F, Screaton GR. Expression of TRAIL and TRAIL receptors in normal and malignant tissues. Cell Res 2005;15:430-8. [PMID: 15987601 DOI: 10.1038/sj.cr.7290311] [Cited by in Crossref: 109] [Cited by in F6Publishing: 98] [Article Influence: 6.4] [Reference Citation Analysis]
7 Klose R, Kemter E, Bedke T, Bittmann I, Keler B, Endres R, Pfeffer K, Schwinzer R, Wolf E. Expression of Biologically Active Human TRAIL in Transgenic Pigs. Transplantation 2005;80:222-30. [DOI: 10.1097/01.tp.0000164817.59006.c2] [Cited by in Crossref: 50] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
8 Amarante-Mendes GP, Griffith TS. Therapeutic applications of TRAIL receptor agonists in cancer and beyond. Pharmacol Ther 2015;155:117-31. [PMID: 26343199 DOI: 10.1016/j.pharmthera.2015.09.001] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
9 Grabarczyk P, Przybylski GK, Depke M, Völker U, Bahr J, Assmus K, Bröker BM, Walther R, Schmidt CA. Inhibition of BCL11B expression leads to apoptosis of malignant but not normal mature T cells. Oncogene 2007;26:3797-810. [PMID: 17173069 DOI: 10.1038/sj.onc.1210152] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 3.2] [Reference Citation Analysis]
10 Chen L, Liu X, Zhu Y, Cao Y, Sun L, Jin B. Localization and variation of TRAIL and its receptors in human placenta during gestation. Life Sciences 2004;74:1479-86. [DOI: 10.1016/j.lfs.2003.07.044] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
11 Song CJ, Liu XS, Zhu Y, Chen LH, Jia W, Li YN, Cao YX, Xie X, Zhuang R, Zhu CS. Expression of TRAIL, DR4, and DR5 in kidney and serum from patients receiving renal transplantation. Transplant Proc. 2004;36:1340-1343. [PMID: 15251327 DOI: 10.1016/j.transproceed.2004.05.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
12 Cretney E, Uldrich AP, Berzins SP, Strasser A, Godfrey DI, Smyth MJ. Normal thymocyte negative selection in TRAIL-deficient mice. J Exp Med. 2003;198:491-496. [PMID: 12900523 DOI: 10.1084/jem.20030634] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 2.8] [Reference Citation Analysis]
13 Falschlehner C, Schaefer U, Walczak H. Following TRAIL's path in the immune system. Immunology. 2009;127:145-154. [PMID: 19476510 DOI: 10.1111/j.1365-2567.2009.03058.x] [Cited by in Crossref: 178] [Cited by in F6Publishing: 179] [Article Influence: 13.7] [Reference Citation Analysis]
14 Cretney E, Uldrich AP, McNab FW, Godfrey DI, Smyth MJ. No requirement for TRAIL in intrathymic negative selection. Int Immunol 2008;20:267-76. [PMID: 18192669 DOI: 10.1093/intimm/dxm144] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
15 Green DR. The suicide in the thymus, a twisted trail. Nat Immunol 2003;4:207-8. [DOI: 10.1038/ni0303-207] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
16 Kimberley FC, Screaton GR. Following a TRAIL: update on a ligand and its five receptors. Cell Res 2004;14:359-72. [PMID: 15538968 DOI: 10.1038/sj.cr.7290236] [Cited by in Crossref: 165] [Cited by in F6Publishing: 151] [Article Influence: 9.7] [Reference Citation Analysis]
17 Vrazo AC, Hontz AE, Figueira SK, Butler BL, Ferrell JM, Binkowski BF, Li J, Risma KA. Live cell evaluation of granzyme delivery and death receptor signaling in tumor cells targeted by human natural killer cells. Blood 2015;126:e1-e10. [PMID: 26124495 DOI: 10.1182/blood-2015-03-632273] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
18 Szretter KJ, Gangappa S, Lu X, Smith C, Shieh WJ, Zaki SR, Sambhara S, Tumpey TM, Katz JM. Role of host cytokine responses in the pathogenesis of avian H5N1 influenza viruses in mice. J Virol 2007;81:2736-44. [PMID: 17182684 DOI: 10.1128/JVI.02336-06] [Cited by in Crossref: 292] [Cited by in F6Publishing: 205] [Article Influence: 18.3] [Reference Citation Analysis]
19 Nebozhyn M, Loboda A, Kari L, Rook AH, Vonderheid EC, Lessin S, Berger C, Edelson R, Nichols C, Yousef M, Gudipati L, Shang M, Showe MK, Showe LC. Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy. Blood 2006;107:3189-96. [PMID: 16403914 DOI: 10.1182/blood-2005-07-2813] [Cited by in Crossref: 75] [Cited by in F6Publishing: 63] [Article Influence: 4.7] [Reference Citation Analysis]
20 Chen LH, Liu XS, Wang WY, Han WN, Pan BR, Jin BQ. Localization of TRAIL/TRAILR in fetal pancreas. World J Gastroenterol 2003; 9(2): 334-337 [PMID: 12532461 DOI: 10.3748/wjg.v9.i2.334] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
21 Colucci S, Brunetti G, Rizzi R, Zonno A, Mori G, Colaianni G, Del Prete D, Faccio R, Liso A, Capalbo S. T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood. 2004;104:3722-3730. [PMID: 15308561 DOI: 10.1182/blood-2004-02-0474] [Cited by in Crossref: 103] [Cited by in F6Publishing: 95] [Article Influence: 5.7] [Reference Citation Analysis]
22 Raftery MJ, Schwab M, Eibert SM, Samstag Y, Walczak H, Schönrich G. Targeting the function of mature dendritic cells by human cytomegalovirus: a multilayered viral defense strategy. Immunity. 2001;15:997-1009. [PMID: 11754820 DOI: 10.1016/s1074-7613(01)00239-4] [Cited by in Crossref: 164] [Cited by in F6Publishing: 80] [Article Influence: 8.2] [Reference Citation Analysis]
23 Hoffmann O, Zipp F, Weber JR. Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in central nervous system inflammation. J Mol Med 2009;87:753-63. [DOI: 10.1007/s00109-009-0484-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
24 Kang S, Park EJ, Joe Y, Seo E, Park MK, Seo SY, Chung HY, Yoo YH, Kim DK, Lee HJ. Systemic delivery of TNF-related apoptosis-inducing ligand (TRAIL) elevates levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and prevents type 1 diabetes in nonobese diabetic mice. Endocrinology. 2010;151:5638-5646. [PMID: 21047948 DOI: 10.1210/en.2009-0478] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
25 Cretney E, Uldrich AP, Berzins SP, Strasser A, Godfrey DI, Smyth MJ. Are we really on the right TRAIL? Immunol Res 2005;31:161-4. [PMID: 15778513 DOI: 10.1385/IR:31:2:161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
26 Cardoso Alves L, Corazza N, Micheau O, Krebs P. The multifaceted role of TRAIL signaling in cancer and immunity. FEBS J 2020. [PMID: 33215853 DOI: 10.1111/febs.15637] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
27 Hernandez JB, Newton RH, Walsh CM. Life and death in the thymus--cell death signaling during T cell development. Curr Opin Cell Biol 2010;22:865-71. [PMID: 20810263 DOI: 10.1016/j.ceb.2010.08.003] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
28 Lamhamedi-Cherradi SE, Zheng SJ, Maguschak KA, Peschon J, Chen YH. Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice. Nat Immunol. 2003;4:255-260. [PMID: 12577054 DOI: 10.1038/ni894] [Cited by in Crossref: 239] [Cited by in F6Publishing: 233] [Article Influence: 12.6] [Reference Citation Analysis]
29 Xu G, Shi Y. Apoptosis signaling pathways and lymphocyte homeostasis. Cell Res. 2007;17:759-771. [PMID: 17576411 DOI: 10.1038/cr.2007.52] [Cited by in Crossref: 108] [Cited by in F6Publishing: 102] [Article Influence: 7.7] [Reference Citation Analysis]
30 Staniek J, Lorenzetti R, Heller B, Janowska I, Schneider P, Unger S, Warnatz K, Seidl M, Venhoff N, Thiel J, Smulski CR, Rizzi M. TRAIL-R1 and TRAIL-R2 Mediate TRAIL-Dependent Apoptosis in Activated Primary Human B Lymphocytes. Front Immunol 2019;10:951. [PMID: 31114586 DOI: 10.3389/fimmu.2019.00951] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
31 Li R, Lim A, Phoon MC, Narasaraju T, Ng JK, Poh WP, Sim MK, Chow VT, Locht C, Alonso S. Attenuated Bordetella pertussis protects against highly pathogenic influenza A viruses by dampening the cytokine storm. J Virol 2010;84:7105-13. [PMID: 20444902 DOI: 10.1128/JVI.02542-09] [Cited by in Crossref: 52] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
32 Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, Tanner JE, Sayers TJ, Seki N, Okumura K, Yagita H, Smyth MJ. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 2004;199:437-48. [PMID: 14769851 DOI: 10.1084/jem.20031457] [Cited by in Crossref: 152] [Cited by in F6Publishing: 138] [Article Influence: 8.4] [Reference Citation Analysis]
33 Liu X, Zhu Y, Han W, Li Y, Chen L, Jia W, Song C, Liu F, Yang K, Li Q, Jin B. Preparation and Characterization of a Set of Monoclonal Antibodies to TRAIL and TRAIL Receptors DR4, DR5, DcR1, and DcR2. Hybridoma and Hybridomics 2003;22:121-5. [DOI: 10.1089/153685903321948058] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
34 Hawkins CJ. TRAIL and Malignant Glioma. TRAIL (TNF-Related Apoptosis-Inducing Ligand). Elsevier; 2004. pp. 427-52. [DOI: 10.1016/s0083-6729(04)67022-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
35 Cretney E, Shanker A, Yagita H, Smyth MJ, Sayers TJ. TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol Cell Biol. 2006;84:87-98. [PMID: 16405656 DOI: 10.1111/j.1440-1711.2005.01413.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 4.0] [Reference Citation Analysis]
36 Corazza N, Brumatti G, Jakob S, Villunger A, Brunner T. TRAIL and thymocyte apoptosis: not so deadly. Cell Death Differ. 2004;11 Suppl 2:S213-S215. [PMID: 15514674 DOI: 10.1038/sj.cdd.4401525] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
37 Lee HO, Herndon JM, Barreiro R, Griffith TS, Ferguson TA. TRAIL: a mechanism of tumor surveillance in an immune privileged site. J Immunol. 2002;169:4739-4744. [PMID: 12391182 DOI: 10.4049/jimmunol.169.9.4739] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 3.4] [Reference Citation Analysis]
38 Audo R, Combe B, Hahne M, Morel J. The two directions of TNF-related apoptosis-inducing ligand in rheumatoid arthritis. Cytokine 2013;63:81-90. [DOI: 10.1016/j.cyto.2013.04.011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
39 Greil R, Anether G, Johrer K, Tinhofer I. Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic tools. J Leukoc Biol 2003;74:311-30. [PMID: 12949235 DOI: 10.1189/jlb.0802416] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
40 Shepard BD, Badley AD. The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases. Antiinfect Agents Med Chem 2009;8:87-101. [PMID: 21857885 DOI: 10.2174/187152109787846060] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
41 Colucci S, Brunetti G, Cantatore FP, Oranger A, Mori G, Pignataro P, Tamma R, Grassi FR, Zallone A, Grano M. The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis. Apoptosis 2007;12:1623-32. [DOI: 10.1007/s10495-007-0095-3] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 2.7] [Reference Citation Analysis]
42 Corazza N, Brumatti G, Schaer C, Cima I, Wasem C, Brunner T. TRAIL and immunity: more than a license to kill tumor cells. Cell Death Differ 2004;11 Suppl 2:S122-5. [PMID: 15608691 DOI: 10.1038/sj.cdd.4401542] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]